Vaxcyte Jumps on Phase 3 Vaccine Win as Biotech Stocks Set Records
Vaxcyte shares shot up 31 percent after strong Phase 3 results for its pneumococcal vaccine. The news sparked a rally, sending several biotech stocks to fresh 52-week highs.
Vaxcyte shares shot up 31 percent after strong Phase 3 results for its pneumococcal vaccine. The news sparked a rally, sending several biotech stocks to fresh 52-week highs.